Breaking News Instant updates and real-time market news.

NUS

Nu Skin

$51.13 /

+0.95 (+1.89%)

16:52
10/01/20
10/01
16:52
10/01/20
16:52

Nu Skin sees Q3 revenue $700M-$703M, consensus $664.29M

Nu Skin Enterprises, Inc. estimated third-quarter 2020 revenue of $700M-$703M, well ahead of its previous guidance of $605M-$635M. "Driven primarily by ongoing investment in our digitally enabled business model and our strong product portfolio, we significantly grew both customers and sales leaders in the third quarter," said Ritch Wood, chief executive officer. "Our results also benefited from the current environment where consumers are spending more time online and working from home, as sales leaders leverage the power of social sharing to achieve greater levels of productivity. Digital transactions accounted for approximately 90 percent of sales this quarter. We are also pleased with greater geographic balance in our business driven by continued expansion in the West, as well as sequential improvement in China and strong growth in our manufacturing segment. These results provide increased momentum as we head into the fourth quarter, with growing anticipation for the global previews of our new ageLOC Boost device and Nutricentials Bioadaptive Skin Care line."

NUS Nu Skin
$51.13 /

+0.95 (+1.89%)

09/30/20 Jefferies
Nu Skin price target raised to $60 from $57 at Jefferies
09/11/20 Jefferies
Herbalife, Nu Skin valuation gaps can close as models transform, says Jefferies
08/06/20 Jefferies
Nu Skin price target raised to $57 from $50 at Jefferies
08/06/20 DA Davidson
Nu Skin price target raised to $61 from $54 at DA Davidson

TODAY'S FREE FLY STORIES

Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/24/20
10/24
04:55
10/24/20
04:55
AKBA

Akebia

$3.18 /

-0.065 (-2.01%)

, ALNY

Alnylam

$131.62 /

-2.7 (-2.01%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$227.06 /

-0.84 (-0.37%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

, BAX

Baxter

$81.08 /

-0.35 (-0.43%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$26.00 /

-1.16 (-4.27%)

, ICUI

ICU Medical

$192.47 /

-2.01 (-1.03%)

, TCDA

Tricida

$8.74 /

-0.17 (-1.91%)

, SNY

Sanofi

$49.33 /

+0.39 (+0.80%)

, GSK

GlaxoSmithKline

$35.30 /

+0.22 (+0.63%)

, FOLD

Amicus

$18.48 /

+0.455 (+2.52%)

, FMS

Fresenius Medical

$40.87 /

+0.75 (+1.87%)

, DRNA

Dicerna

$19.38 /

-0.32 (-1.62%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$58.92 /

+3.93 (+7.15%)

, KDNY

Chinook Therapeutics

$15.34 /

-0.1 (-0.65%)

, RTRX

Retrophin

$20.91 /

-0.12 (-0.57%)

, OMER

Omeros

$10.66 /

-0.4 (-3.62%)

, OM

Outset Medical

$50.00 /

+1.8 (+3.73%)

, NVS

Novartis

$84.41 /

-0.04 (-0.05%)

, VRTX

Vertex Pharmaceuticals

$211.52 /

+1.34 (+0.64%)

Kidney Week 2020: Virtual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AKBA Akebia
$3.18 /

-0.065 (-2.01%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$227.06 /

-0.84 (-0.37%)

10/22/20 Oppenheimer
Amgen price target lowered to $275 from $280 at Oppenheimer
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
BAX Baxter
$81.08 /

-0.35 (-0.43%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.74 /

-0.17 (-1.91%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$18.48 /

+0.455 (+2.52%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 SunTrust
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$10.66 /

-0.4 (-3.62%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$50.00 /

+1.8 (+3.73%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.41 /

-0.04 (-0.05%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
AKBA Akebia
$3.18 /

-0.065 (-2.01%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
AKBA Akebia
$3.18 /

-0.065 (-2.01%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

OM Outset Medical
$50.00 /

+1.8 (+3.73%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

Hot Stocks
Mattel CEO: Our strategy is clearly working » 18:28
10/23/20
10/23
18:28
10/23/20
18:28
MAT

Mattel

$14.16 /

+1.23 (+9.51%)

In an interview on…

In an interview on CNBC's Mad Money, Ynon Kreiz said Mattel had a strong upswing in revenue and profitability in Q3 with gross margin at 51%. "Our brands and product offerings resonate with consumers and parents continue to spend on their children," Kreiz noted. He said Barbie is doing amazingly well with demand up 50%. "We are seeing a strong demand for our products and there is a lot of momentum heading into the holiday season," Kreiz added.

ShowHide Related Items >><<
MAT Mattel
$14.16 /

+1.23 (+9.51%)

MAT Mattel
$14.16 /

+1.23 (+9.51%)

10/23/20
Fly Intel: Top five analyst upgrades
10/23/20 JPMorgan
Mattel price target raised to $20 from $17.50 at JPMorgan
10/23/20 JPMorgan
Hasbro price target raised to $92 from $83 at JPMorgan
10/23/20 DA Davidson
Mattel upgraded to Buy at DA Davidson after 'outstanding' Q3 results
MAT Mattel
$14.16 /

+1.23 (+9.51%)

MAT Mattel
$14.16 /

+1.23 (+9.51%)

MAT Mattel
$14.16 /

+1.23 (+9.51%)

Periodicals
Judge rejects CA claims against Juul in youth vaping cases, Bloomberg says » 18:24
10/23/20
10/23
18:24
10/23/20
18:24
MO

Altria Group

$39.09 /

+0.09 (+0.23%)

Juul is 35% owned by…

Juul is 35% owned by Altria, The Fly notes.

ShowHide Related Items >><<
MO Altria Group
$39.09 /

+0.09 (+0.23%)

MO Altria Group
$39.09 /

+0.09 (+0.23%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Barclays
Altria downgraded to Equal Weight on share losses at Barclays
07/08/20 Barclays
Altria Group downgraded to Equal Weight from Overweight at Barclays
07/07/20 Stifel
IQOS reduced exposure claim a 'win' for Philip Morris, Altria, says Stifel
MO Altria Group
$39.09 /

+0.09 (+0.23%)

MO Altria Group
$39.09 /

+0.09 (+0.23%)

MO Altria Group
$39.09 /

+0.09 (+0.23%)

MO Altria Group
$39.09 /

+0.09 (+0.23%)

Periodicals
Facebook demands shutdown of NYU political ad research project, WSJ says » 17:36
10/23/20
10/23
17:36
10/23/20
17:36
FB

Facebook

$284.89 /

+6.78 (+2.44%)

Facebook is demanding…

Facebook is demanding that a New York University research project stop collecting information about its political-ad targeting practices, establishing a fight with an academic institution seeking to study the platform with the social media giant's consent, the Wall Street Journal's Jeff Horwitz reports. The conflict involves the NYU Ad Observatory, a project that rolled out last month that has recruited over 6,500 volunteers to use a specifically designed browser extension to gather data bout the political ads Facebook shows them, Horwitz says. Facebook issued a letter to the researchers behind the project last week, claiming the project violates provisions in its terms of services that block bulk data collection from its site, the author notes. Reference Link

ShowHide Related Items >><<
FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

10/22/20 Argus
Snap price target raised to $50 from $30 at Argus
10/20/20 Jefferies
Facebook price target raised to $320 from $310 at Jefferies
10/20/20 Credit Suisse
Facebook price target raised to $322 from $315 at Credit Suisse
10/15/20 Cowen
Trump unhappiness may reinforce odds of antitrust action on Facebook, says Cowen
FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

Hot Stocks
SPDR Gold Shares holdings fall to 1,263.80MT from 1,265.55MT » 17:34
10/23/20
10/23
17:34
10/23/20
17:34
GLD

SPDR Gold Shares

$178.66 /

-0.16 (-0.09%)

This is the 4th…

This is the 4th consecutive decrease and the lowest level of holdings since September 18th.

ShowHide Related Items >><<
GLD SPDR Gold Shares
$178.66 /

-0.16 (-0.09%)

GLD SPDR Gold Shares
$178.66 /

-0.16 (-0.09%)

Syndicate
Mustang Bio files $100M mixed securities shelf  17:32
10/23/20
10/23
17:32
10/23/20
17:32
MBIO

Mustang Bio

$2.95 /

+0.12 (+4.24%)

 
ShowHide Related Items >><<
MBIO Mustang Bio
$2.95 /

+0.12 (+4.24%)

MBIO Mustang Bio
$2.95 /

+0.12 (+4.24%)

10/02/20 B. Riley Securities
B. Riley starts Mustang Bio at Buy, sees 200% potential upside
10/02/20 B. Riley Securities
Mustang Bio initiated with a Buy at B. Riley Securities
10/01/20 Oppenheimer
Mustang Bio reached 'important milestone' with trial start, says Oppenheimer
08/17/20 Oppenheimer
Mustang Bio in position for Priority Review Voucher, says Oppenheimer
MBIO Mustang Bio
$2.95 /

+0.12 (+4.24%)

  • 11
    Jun
MBIO Mustang Bio
$2.95 /

+0.12 (+4.24%)

Syndicate
Acuity Brands files automatic mixed securities shelf  17:28
10/23/20
10/23
17:28
10/23/20
17:28
AYI

Acuity Brands

$94.63 /

-0.7 (-0.73%)

 
ShowHide Related Items >><<
AYI Acuity Brands
$94.63 /

-0.7 (-0.73%)

AYI Acuity Brands
$94.63 /

-0.7 (-0.73%)

09/16/20 UBS
Acuity Brands initiated with a Sell at UBS
09/15/20 UBS
Acuity Brands initiated with a Sell at UBS
07/01/20 William Blair
William Blair says Acuity margins surprise, still cautious on sustainability
07/01/20 Roth Capital
Roth Capital says checks show Acuity Brands' number 1 customer lost
AYI Acuity Brands
$94.63 /

-0.7 (-0.73%)

AYI Acuity Brands
$94.63 /

-0.7 (-0.73%)

AYI Acuity Brands
$94.63 /

-0.7 (-0.73%)

Syndicate
AC Immune files to 12M common shares for holders  17:25
10/23/20
10/23
17:25
10/23/20
17:25
ACIU

AC Immune

$4.98 /

+0.21 (+4.40%)

 
ShowHide Related Items >><<
ACIU AC Immune
$4.98 /

+0.21 (+4.40%)

ACIU AC Immune
$4.98 /

+0.21 (+4.40%)

08/21/20 SVB Leerink
AC Immune upcoming readout risk-reward skews positive, says SVB Leerink
12/10/19 H.C. Wainwright
AC Immune price target raised to $11 from $8 at H.C. Wainwright
ACIU AC Immune
$4.98 /

+0.21 (+4.40%)

ACIU AC Immune
$4.98 /

+0.21 (+4.40%)

Hot Stocks
Point72 reports 7.9% passive stake in Bellus Health » 17:25
10/23/20
10/23
17:25
10/23/20
17:25
BLU

Bellus Health

$2.46 /

-0.025 (-1.01%)

Point72 Asset Management…

Point72 Asset Management disclosed a 7.9% stake in Bellus Health, which represents over 6.2M shares. The filing does not allow for activism.

ShowHide Related Items >><<
BLU Bellus Health
$2.46 /

-0.025 (-1.01%)

BLU Bellus Health
$2.46 /

-0.025 (-1.01%)

08/14/20 H.C. Wainwright
Bellus Health price target lowered to $10 from $28 at H.C. Wainwright
07/07/20 Guggenheim
Guggenheim downgrades Bellus Health to Neutral after 'disappointing' cough trial
07/07/20 Guggenheim
Bellus Health downgraded to Neutral from Buy at Guggenheim
07/06/20 Jefferies
Jefferies cuts Bellus target to $6, sees potential for 'meaningful upside'
  • 20
    Oct
BLU Bellus Health
$2.46 /

-0.025 (-1.01%)

Hot Stocks
iCAD to showcase expanded platform for Xoft Axxent system at ASTRO » 17:08
10/23/20
10/23
17:08
10/23/20
17:08
ICAD

iCAD

$11.49 /

+0.27 (+2.41%)

The company states:…

The company states: "iCAD announced that the company will showcase the expanded platform for the Xoft Axxent Electronic Brachytherapy System at the American Society for Radiation Oncology, or ASTRO, Virtual Annual Meeting, October 24-28, 2020. Researchers will present new data supporting the Xoft System for the treatment of early-stage breast cancer and gynecological cancers, as the company showcases the latest in technology for Xoft including its full suite of applicators for existing and emerging applications in the virtual Xoft exhibition booth. The Xoft System is a 50 kV radiation oncology treatment solution that uses a miniaturized X-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site while minimizing risk of damage to healthy tissue in nearby areas of the body. The isotope-free radiation requires minimal shielding, enabling medical professionals to remain in the room during treatment."

ShowHide Related Items >><<
ICAD iCAD
$11.49 /

+0.27 (+2.41%)

ICAD iCAD
$11.49 /

+0.27 (+2.41%)

02/13/20 Craig-Hallum
iCAD price target raised to $15 from $9 at Craig-Hallum
02/05/20 JMP Securities
iCAD initiated with an Outperform at JMP Securities
01/09/20 Lake Street
Lake Street starts 'disruptive' iCAD with Buy rating, $14 price target
12/20/19
iCAD initiated with a Buy at Dougherty
ICAD iCAD
$11.49 /

+0.27 (+2.41%)

ICAD iCAD
$11.49 /

+0.27 (+2.41%)

Hot Stocks
Kraft Heinz chief growth officer Barton to leave company » 17:07
10/23/20
10/23
17:07
10/23/20
17:07
KHC

Kraft Heinz

$31.36 /

+0.16 (+0.51%)

In a regulatory filing,…

In a regulatory filing, Kraft Heinz said that, on October 23, 2020, chief growth officer Nina Barton decided to leave the company to pursue other career opportunities. Barton has agreed to continue her employment with the company until May 31, 2021 in a new role as Strategic Advisor effective November 30, 2020.

ShowHide Related Items >><<
KHC Kraft Heinz
$31.36 /

+0.16 (+0.51%)

KHC Kraft Heinz
$31.36 /

+0.16 (+0.51%)

09/16/20
Fly Intel: Top five analyst upgrades
09/16/20 JPMorgan
Kraft Heinz risk/reward remains favorable, says JPMorgan
09/16/20 Guggenheim
Guggenheim upgrades Kraft Heinz to Neutral after 'strong' investor day
09/16/20 Guggenheim
Kraft Heinz upgraded to Neutral from Sell at Guggenheim
KHC Kraft Heinz
$31.36 /

+0.16 (+0.51%)

KHC Kraft Heinz
$31.36 /

+0.16 (+0.51%)

KHC Kraft Heinz
$31.36 /

+0.16 (+0.51%)

KHC Kraft Heinz
$31.36 /

+0.16 (+0.51%)

Syndicate
Co-Diagnostics files $100M mixed securities shelf  17:06
10/23/20
10/23
17:06
10/23/20
17:06
CODX

Co-Diagnostics

$12.47 /

+0.38 (+3.14%)

 
ShowHide Related Items >><<
CODX Co-Diagnostics
$12.47 /

+0.38 (+3.14%)

CODX Co-Diagnostics
$12.47 /

+0.38 (+3.14%)

05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/18/20 H.C. Wainwright
Co-Diagnostics price target raised to $35 from $20 at H.C. Wainwright
03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
CODX Co-Diagnostics
$12.47 /

+0.38 (+3.14%)

CODX Co-Diagnostics
$12.47 /

+0.38 (+3.14%)

CODX Co-Diagnostics
$12.47 /

+0.38 (+3.14%)

CODX Co-Diagnostics
$12.47 /

+0.38 (+3.14%)

Hot Stocks
Galera reports 'positive' interim data from first patient cohort in GC4419 trial » 17:03
10/23/20
10/23
17:03
10/23/20
17:03
GRTX

Galera Therapeutics

$12.44 /

+0.64 (+5.42%)

Galera Therapeutics…

Galera Therapeutics announced the release of the abstract containing interim data from the first 19 patients in its pilot Phase 1/2 clinical trial designed to evaluate the safety and efficacy of avasopasem manganese in combination with stereotactic body radiation therapy, compared with SBRT and placebo, in patients with locally advanced pancreatic cancer. The interim data were shared in abstract #LBA5 on the 2020 American Society for Radiation Oncology Annual Meeting virtual program website. Galera's investigational, highly selective small molecule superoxide dismutase (SOD) mimetics are designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen. These dismutase mimetics have potential anti-cancer synergy based on positive results in multiple preclinical models. In the initial analysis of the intent-to-treat cohort enrolled in the first, single-center stage of the trial, which comprises all patients followed for over a year, median overall survival had not yet been reached in the GC4419 arm, compared to 40.4 weeks in the placebo arm. The GC4419 arm also demonstrated favorable progression-free survival, locoregional control and time-to-distant metastases compared to the placebo arm. The incidence of acute or late Grade 3+ toxicity post-SBRT was similar in both arms.

ShowHide Related Items >><<
GRTX Galera Therapeutics
$12.44 /

+0.64 (+5.42%)

GRTX Galera Therapeutics
$12.44 /

+0.64 (+5.42%)

10/02/20 Citi
Citi opens 'positive catalyst watch' on Galera Therapeutics
12/02/19 BTIG
Galera Therapeutics initiated with a Buy at BTIG
12/02/19 Credit Suisse
Galera Therapeutics initiated with a Neutral at Credit Suisse
12/02/19 Citi
Galera Therapeutics initiated with a Buy at Citi
GRTX Galera Therapeutics
$12.44 /

+0.64 (+5.42%)

  • 07
    Nov
Syndicate
Hyliion Holdings files to sell 132.6M shares of common stock for holders  17:02
10/23/20
10/23
17:02
10/23/20
17:02
HYLN

Hyliion Holdings

$22.10 /

-2.22 (-9.13%)

 
ShowHide Related Items >><<
HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

10/15/20 Goldman Sachs
Hyliion Holdings initiated with a Neutral at Goldman Sachs
HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

Syndicate
Hyliion Holdings files to sell 19.2M shares of stock issuable on warrant  17:01
10/23/20
10/23
17:01
10/23/20
17:01
HYLN

Hyliion Holdings

$22.10 /

-2.22 (-9.13%)

 
ShowHide Related Items >><<
HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

10/15/20 Goldman Sachs
Hyliion Holdings initiated with a Neutral at Goldman Sachs
HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

HYLN Hyliion Holdings
$22.10 /

-2.22 (-9.13%)

Hot Stocks
WidePoint to effectuate 1-for-10 reverse stock split » 17:00
10/23/20
10/23
17:00
10/23/20
17:00
WYY

WidePoint

$0.55 /

-0.019 (-3.33%)

WidePoint Corporation…

WidePoint Corporation announced that a 1-for-10 reverse stock split of the company's common stock will become effective on Friday, November 6, 2020 at 5:00 p.m. Eastern time. Trading of the company's common stock on a post-split basis will begin on Monday, November 9, 2020. On August 24, 2020, the stockholders of the company approved the reverse stock split at a special meeting of stockholders. Subsequent to the meeting's end, the board of directors of the company approved the implementation of the reverse stock split at the ratio of 1-for-10.

ShowHide Related Items >><<
WYY WidePoint
$0.55 /

-0.019 (-3.33%)

WYY WidePoint
$0.55 /

-0.019 (-3.33%)

03/03/20
LD Micro to hold a virtual conference
WYY WidePoint
$0.55 /

-0.019 (-3.33%)

Periodicals
HHS says thousands of facilities opt into CVS, Walgreens vaccine deal, CNBC says » 16:59
10/23/20
10/23
16:59
10/23/20
16:59
CVS

CVS Health

$60.23 /

+0.76 (+1.28%)

, WBA

Walgreens Boots Alliance

$38.05 /

+0.53 (+1.41%)

Paul Mango, a deputy…

Paul Mango, a deputy chief of staff at the U.S. Department of Health and Human Services, said that thousands of long-term care and assisted living facilities have already opted into the White House's program with CVS Health (CVS) and Walgreens (WBA) to administer COVID-19 vaccines to senior citizens, CNBC's Berkeley Lovelace, Jr. reports. On Monday, such facilities started selecting which pharmacy they preferred as part of the program, which is optional, the author notes. Mango said the HHS estimates there are roughly 15,000 long-term care facilities and about 35,000 assisted living facilities in the U.S., and 9,000-10,000 facilities have opted into the program, the author notes. Reference Link

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$38.05 /

+0.53 (+1.41%)

CVS CVS Health
$60.23 /

+0.76 (+1.28%)

CVS CVS Health
$60.23 /

+0.76 (+1.28%)

09/21/20 Citi
Citi sees ACA remaining law despite Ginsburg death
09/17/20
Fly Intel: Top five analyst initiations
09/17/20 Piper Sandler
CVS Health initiated with an Overweight at Piper Sandler
08/06/20 Deutsche Bank
CVS Health price target lowered to $104 from $109 at Deutsche Bank
WBA Walgreens Boots Alliance
$38.05 /

+0.53 (+1.41%)

10/16/20 Citi
Walgreens Boots Alliance price target lowered to $40 from $43 at Citi
10/08/20 Barclays
Walgreens Boots Alliance price target lowered to $40 from $45 at Barclays
10/06/20 Goldman Sachs
Walgreens Boots Alliance price target lowered to $33 from $37 at Goldman Sachs
09/11/20 Mizuho
Walgreens Boots Alliance price target lowered to $37 from $43 at Mizuho
WBA Walgreens Boots Alliance
$38.05 /

+0.53 (+1.41%)

CVS CVS Health
$60.23 /

+0.76 (+1.28%)

WBA Walgreens Boots Alliance
$38.05 /

+0.53 (+1.41%)

CVS CVS Health
$60.23 /

+0.76 (+1.28%)

WBA Walgreens Boots Alliance
$38.05 /

+0.53 (+1.41%)

CVS CVS Health
$60.23 /

+0.76 (+1.28%)

WBA Walgreens Boots Alliance
$38.05 /

+0.53 (+1.41%)

CVS CVS Health
$60.23 /

+0.76 (+1.28%)

Syndicate
Ebang files to sell 5M Class A ordinary shares, warrants to purchase 2.5M shares  16:54
10/23/20
10/23
16:54
10/23/20
16:54
EBON

Ebang

$9.24 /

-0.5 (-5.13%)

 
ShowHide Related Items >><<
EBON Ebang
$9.24 /

-0.5 (-5.13%)

  • 26
    Jun
EBON Ebang
$9.24 /

-0.5 (-5.13%)

Syndicate
Satsuma Pharmaceuticals files $150M mixed securities shelf  16:49
10/23/20
10/23
16:49
10/23/20
16:49
STSA

Satsuma Pharmaceuticals

$4.06 /

+0.11 (+2.78%)

 
ShowHide Related Items >><<
STSA Satsuma Pharmaceuticals
$4.06 /

+0.11 (+2.78%)

STSA Satsuma Pharmaceuticals
$4.06 /

+0.11 (+2.78%)

09/21/20 H.C. Wainwright
Satsuma Pharmaceuticals price target lowered to $7 from $35 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
09/11/20
Fly Intel: Top five analyst downgrades
09/11/20 SVB Leerink
Satsuma Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
STSA Satsuma Pharmaceuticals
$4.06 /

+0.11 (+2.78%)

STSA Satsuma Pharmaceuticals
$4.06 /

+0.11 (+2.78%)

Hot Stocks
Mueller Water raises quarterly dividend to 5.5c per share from 5.25c » 16:47
10/23/20
10/23
16:47
10/23/20
16:47
MWA

Mueller Water

$11.10 /

+0.035 (+0.32%)

The dividend is payable…

The dividend is payable on or about November 20, 2020, to stockholders of record as of the close of business on November 10, 2020.

ShowHide Related Items >><<
MWA Mueller Water
$11.10 /

+0.035 (+0.32%)

MWA Mueller Water
$11.10 /

+0.035 (+0.32%)

04/08/20 Goldman Sachs
Mueller Water upgraded to Neutral from Sell at Goldman Sachs
03/26/20 Berenberg
Mueller Water downgraded to Hold from Buy at Berenberg
03/16/20 Boenning & Scattergood
Mueller Water downgraded to Neutral from Outperform at Boenning & Scattergood
03/16/20 Boenning & Scattergood
Mueller Industries downgraded to Neutral from Outperform at Boenning & Scattergood
MWA Mueller Water
$11.10 /

+0.035 (+0.32%)

Syndicate
New Oriental Education files to sell American depositary shares, no amount given  16:47
10/23/20
10/23
16:47
10/23/20
16:47
EDU

New Oriental Education

$170.43 /

-1.465 (-0.85%)

 
ShowHide Related Items >><<
EDU New Oriental Education
$170.43 /

-1.465 (-0.85%)

EDU New Oriental Education
$170.43 /

-1.465 (-0.85%)

10/15/20 Citi
New Oriental Education price target raised to $198 from $160 at Citi
10/14/20 Benchmark
New Oriental Education price target raised to $195 from $148 at Benchmark
09/02/20
Fly Intel: Top five analyst initiations
09/01/20
New Oriental Education, TAL Education started with a Buy at Jefferies
EDU New Oriental Education
$170.43 /

-1.465 (-0.85%)

EDU New Oriental Education
$170.43 /

-1.465 (-0.85%)

Syndicate
Cohen & Co. files $75M mixed securities shelf  16:45
10/23/20
10/23
16:45
10/23/20
16:45
COHN

Cohen & Co.

$19.59 /

+0.09 (+0.46%)

 
ShowHide Related Items >><<
COHN Cohen & Co.
$19.59 /

+0.09 (+0.46%)

COHN Cohen & Co.
$19.59 /

+0.09 (+0.46%)

General news
Treasury Market Summary » 16:45
10/23/20
10/23
16:45
10/23/20
16:45

Treasury Market Summary:…

Treasury Market Summary: the markets got back to trading following the final presidential debate Thursday night that was much more civil but didn't result in any fresh directional clues. Treasuries recovered from early declines and yields finished richer on the session in a bull flattener. The 10-year and 30-year maturities also broke 6-day losing streaks after hitting the highest rates in months. Also supporting the rally were technicals as T-note challenged the 200-day moving average. The wavering on Wall Street contributed too as the indexes slipped into the red on stimulus disappointments, only to bounce late in the day with the S&amp;P 500 and NASDAQ closing just over 0.3% higher while the Dow was down -0.1%. Earnings news was mixed and light trading exacerbated choppy price action into the weekend. View the summary.

Hot Stocks
Penske Automotive CFO sells 8K shares of common stock » 16:35
10/23/20
10/23
16:35
10/23/20
16:35
PAG

Penske Automotive

$55.15 /

-0.14 (-0.25%)

In a regulatory filing,…

In a regulatory filing, Penske Automotive disclosed that its CFO John Carlson sold 8K shares of common stock on October 23rd in a total transaction size of $445K. The holding represents about 22% of his total owned.

ShowHide Related Items >><<
PAG Penske Automotive
$55.15 /

-0.14 (-0.25%)

PAG Penske Automotive
$55.15 /

-0.14 (-0.25%)

10/19/20 Seaport Global
Penske Automotive initiated with a Buy at Seaport Global
08/27/20 Benchmark
Benchmark sees more strong earnings from auto dealers, ups targets in group
07/17/20
Fly Intel: Top five analyst downgrades
07/17/20 Truist
Penske Automotive price target raised to $55 from $48 at SunTrust
PAG Penske Automotive
$55.15 /

-0.14 (-0.25%)

PAG Penske Automotive
$55.15 /

-0.14 (-0.25%)

PAG Penske Automotive
$55.15 /

-0.14 (-0.25%)

Hot Stocks
SolarWinds signs definitive agreement to acquire SentryOne » 16:35
10/23/20
10/23
16:35
10/23/20
16:35
SWI

SolarWinds

$21.72 /

+0.05 (+0.23%)

SolarWinds announced it…

SolarWinds announced it has signed a definitive agreement to acquire SentryOne, a technology provider of database performance monitoring and DataOps solutions on SQL Server, Azure SQL Database, and the Microsoft Data Platform. The expected addition of the SentryOne products to the SolarWinds portfolio also will amplify the depth and breadth of support SolarWinds can offer for Microsoft and Microsoft Azure environments. The transaction is expected to close later this month.

ShowHide Related Items >><<
SWI SolarWinds
$21.72 /

+0.05 (+0.23%)

SWI SolarWinds
$21.72 /

+0.05 (+0.23%)

10/07/20 Berenberg
SolarWinds initiated with a Buy at Berenberg
08/07/20 Jefferies
SolarWinds price target raised to $22 from $19 at Jefferies
06/24/20 Goldman Sachs
SolarWinds price target raised to $18 from $16 at Goldman Sachs
04/23/20 Credit Suisse
SolarWinds downgraded to Neutral from Outperform at Credit Suisse
SWI SolarWinds
$21.72 /

+0.05 (+0.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.